Articles tagged "Cytomeglovirus"

2022 American Transplant Congress
Efficacy and Safety of Delayed, Low-Dose Valganciclovir in High-Risk Cytomegalovirus Liver Transplant Recipients
S. Anders¹, A. Freeman¹, L. Hutchinson¹, U. Kaszubski¹, M. Janusek¹, A. Hooter², D. Raymond², C. Nguyen²
¹Ochsner Medical Center, New Orleans, LA, ²Xavier University, New Orleans, LA
*Purpose: The goal of this study was to compare the safety and efficacy of a delayed valganciclovir (VGCV) dosing protocol for cytomegalovirus (CMV) prophylaxis in…
2022 American Transplant Congress
Cmv-Specific Cell-Mediated Immune Reconstitution in High-Risk Hematopoietic Cell Transplant Recipients Receiving Letermovir Prophylaxis
M. Z. Abidi¹, K. Garth¹, J. Gutman², A. Weinberg¹
¹Medicine, Infectious Disease, University of Colorado, Aurora, CO, ²Medicine, Hematology and Oncology, University of Colorado, Aurora, CO
*Purpose: In the absence of antiviral prophylaxis following Hematopoietic Cell Transplant (HCT), the incidence of clinically significant cytomegalovirus reactivation (cCMV) is 30% in CMV seropositive…
2022 American Transplant Congress
Combined Metagenomic Viral Detection and Donor-Derived Cell-Free DNA Quantification for Solid Organ Transplant Recipients
R. Sinha¹, C. Rebello², E. Bixler¹, A. Al-Turck¹, A. Berg¹, J. Friedewald², S. Kleiboeker¹
¹Eurofins Viracor, Lees Summit, MO, ²Northwestern University, Chicago, IL
*Purpose: Solid organ transplant recipients are predisposed to opportunistic infections, and current viral diagnostic methods focus on sensitive detection of single pathogens by qPCR. However,…
2022 American Transplant Congress
Use of Viral Specific T Cell Therapy in Solid Organ Transplant Recipients – A Single Center Experience
G. McGraw¹, N. Patel², K. Patel¹, S. Bumb³, A. Govil⁴, M. Anand¹
¹University of Cincinnati, Cincinnati, OH, ²Nephrology, University of Cincinnati, Cincinnati, OH, ³Nephrology, Internal Medicine, University of Cincinnati Medical Center, Blue Ash, OH, ⁴Univ of Cincinnati, Cincinnati, OH
*Purpose: Viral infections such as BK virus (BKV), cytomegalovirus (CMV) and adenovirus after kidney transplantation negatively impact outcomes in solid organ transplant (SOT) recipients despite…
2022 American Transplant Congress
Combined CyTOF and Elispot Investigation of CMV Response Over the First Year Post Kidney Transplantation
T. Jouve¹, L. Donadeu Casassas², S. Hartzell³, E. Crespo², M. Meneghini², A. Torija², P. Cravedi⁴, O. Bestard²
¹Nephrology, Vall d’Hebron Institut de Recerca (VHIR), Grenoble, Spain, ²Nephrology, Vall d’Hebron Institut de Recerca (VHIR), Barcelona, Spain, ³Mount Sinai Hospital, New York, NY, ⁴Mount Sinai, New York, NY
*Purpose: CMV remains a threat for kidney transplant recipients (KTR). Deciphering the impact of CMV on the immune system of KTR has helped improving CMV…
2022 American Transplant Congress
Impact of Cytomegalovirus and BK Virus Infection on Clinical Outcomes in Kidney Transplant Recipients
W. Park, J. Yang, J. Kwon, J. Lim, Y. Kim, J. Paek, K. Jin, S. Han
Division of Nephrology, Department of Internal Medicine, Keimyung University School of Medicine, Keimyung University Dongsan Hospital, Daegu, Korea, Republic of
*Purpose: Cytomegalovirus (CMV) or BK virus (BKV) infection is one of the important opportunistic infections in kidney transplant recipients (KTRs). CMV or BKV infection can…
2022 American Transplant Congress
The Evolution of Hypogammaglobulinemia in Kidney Transplant Recipients and Its Associated Risk Factors
E. Jo¹, S. Min², A. Han³
¹Surgery, Seoul National University Hospital, Seoul, Korea, Republic of, ²Surgery, Seoul National University College of Medicine, Seoul, Kosovo, Republic of, ³Seoul National University College of Medicine, Seoul, Korea, Republic of
*Purpose: Hypogammaglobulinemia (HGG) has been extensively studied to identify a biological marker for infection. According to Florescu et al. (2013), a meta-analysis of 18 clinical…
2022 American Transplant Congress
CMV Specific T Cell Immune Response in Hepatitis C Negative Kidney Transplant Recipients Receiving Transplant from Hepatitis C Viremic Donors and Hepatitis C Negative Donors
M. Z. Molnar¹, M. Tsujita², M. Talwar², V. Balaraman², A. Bhalla², J. D. Eason², S. S. Nouer², K. Sumida², A. Remport³, I. E. Hall¹, R. Griffin², G. George Rofaiel⁴, A. Azhar⁵
¹Department of Internal Medicine, Division of Nephrology & Hypertension, University of Utah, Salt Lake City, UT, ²University of Tennessee Health Science Center, Memphis, TN, ³Semmelweis University, Budapest, Hungary, ⁴Department of Surgery, Division of Transplantation and Advanced Hepatobiliary Surgery, University of Utah, Salt Lake City, UT, ⁵Division of Nephrology, Department of Medicine, Virginia Commonwealth University School of Medicine, Richmond, VA
*Purpose: Kidney transplants (KT) from hepatitis C (HCV) viremic donors to HCV negative recipients has shown promising short-term and long-term outcomes. However, high incidence of…
2022 American Transplant Congress
Infections in Kidney Transplant Recipients on Belatacept versus Tacrolimus-Based Immunosuppression
S. Gattis¹, A. Basu²
¹Emory Healthcare, Atlanta, GA, ²Emory University Hospital, Atlanta, GA
*Purpose: Patients 70 years and older with advanced/ end stage kidney disease are increasingly receiving kidney transplants. Immediately post- transplant, our center utilizes Belatacept coupled…
2022 American Transplant Congress
Increasing Proportion of High-Risk Cytomegalovirus (CMV) Donor Positive/recipient Negative (D+R-) Serostatus in Solid Organ Transplant Recipients (SOTRs)
H. Imlay¹, M. M. Wagener², N. Singh², A. P. Limaye³
¹University of Utah, Salt Lake City, UT, ²University of Pittsburgh, Pittsburgh, PA, ³University of Washington, Seattle, WA
*Purpose: CMV D+R- serostatus is independently associated with worse long-term graft and patient survival across many organ transplant types despite current prevention and treatment strategies.…